Introduction
The presence of HIV-1-infected cells within the central nervous system (CNS) remains an important facet of the disease. Brain-resident glial cell populations including microglia and astrocytes are infected by the virus [1, 2] , negatively impacting the functionality and viability of surrounding neurons through mechanisms involving pro-inflammatory cytokine release [3] [4] [5] , neurotrophic dysregulation [6, 7] , aberrant glutamate homeostasis [8, 9] , and direct damage from viral protein production [10, 11] . These mechanisms are thought to contribute to the development of HIV-associated neurocognitive disorders (HAND), a spectrum disorder which adversely affects cognitive, motor, and behavioral processes [12, 13] . Furthermore, it has been established that microglia harbor latent provirus [1, 14] , which can be activated by certain pro-inflammatory stimuli [e.g. interleukin-1b, tumor necrosis factor-a (TNF-a)], leads to productive viral replication [15] . Thus, the microglia within the CNS may serve as 'viral reservoirs', allowing for viral compartmentalization, evolution, and escape [16, 17] . Understanding the pathobiology of HIV-infected microglia is paramount to the development of novel therapeutic approaches that delay or cure HIV-mediated pathogenesis in the CNS.
To date, the models used to study HIV-infected microglia are limited. For in vitro studies, a common method involves the introduction of one or more recombinant HIV viral proteins (e.g. tat, nef, gp120) into microglia/neuronal cultures and assessing the proinflammatory/cytotoxic effects [18] [19] [20] . While this method is useful to identify the individual contributions of viral proteins in microglial activation, the relevance to neuroinflammation caused by HIV-infected microglia releasing these factors in combination is unclear. For example, understanding how the state of microglia influences transcriptional regulation and viral protein production from a harbored provirus is not possible from exposure of single viral proteins. One approach to address this issue is the use of primary cultures of human microglia infected with strains of HIV [21, 22] leading to productive infection and the release of infectious virus and viral proteins. However, the limited availability and the rigorous culture conditions necessary to utilize primary human microglia are a disadvantage when compared with microglial cell lines. Therefore, a reusable microglia model which harbors a stably integrated HIV provirus and allows consistent high throughput experimentation would be of value.
The microglia cell line CHME-5 was originally created through SV40 transfection of human embryonic brain-derived macrophages [23] . Recent studies have used this cell line to examine microglia processes including toll-like receptor expression and signaling [24] , arginase activity [25] , and drug abuse/HIV mediated impact on microglial energetic metabolism [26] . However, recent data acquired from PCR analysis of human vs. rat CYCT1 show that CHME-5 cells are rat in origin [27] . Given their established properties of a microglial cell, we chose to use this cell line to express our modified HIV provirus to allow for comparisons with previously published data on CHME-5/ HIV cell lines [28] .
Here, our laboratory utilized the clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 system and integrated a modified HIV provirus. This modified provirus has the Gag-Pol region replaced by NanoLuciferase (NanoLuc), which has the dual purpose of rendering the provirus replication defective and creating a rapid and robust assay for monitoring the transcriptional activity associated with the long terminal repeat (LTR). Furthermore, coding regions for the neurotoxic viral proteins such as tat, nef and gp120 remain intact. In this study, we generated stable cell lines by integrating a modified HIV provirus and compared the LTR activity and pro-inflammatory phenotype of four selected clones. Using pharmacological and genetic manipulation, we demonstrated that the modified provirus expresses a NanoLuc reporter and viral proteins in a manner consistent with activity of a wild-type HIV provirus. Collectively, we developed an in vitro model of HIV-infected microglia to study the pathobiology and evaluate therapeutics for HIVassociated neuroinflammation and neurodegeneration.
Results
Generation of a stable microglial cell line containing a modified HIV provirus targeted to the ROSA26 locus
We designed a targeting construct to integrate a replication-defective HIV (YU-2, M-tropic) provirus in the ROSA26 locus (Fig. 1A) , a 'safe harbor' locus for expressing transgenes based on their cis-containing elements [29] . A safe harbor locus is an area of the genome that is resistant to epigenetic silencing, ubiquitously expressed in all tissues, and the transcription of surrounding genes remains intact after foreign transgene insertion. In our modified HIV provirus, the gag-pol genes were replaced with a NanoLuc coding sequence to enable monitoring of HIV LTR activation. The resulting construct, 'HIV-NanoLuc' (Fig. 1A) was co-transfected with plasmids expressing Cas9 nickase (Cas9n) and guide RNAs (gRNAs) targeting the ROSA26 locus of CHME-5 cells, a microglia cell line. The nickase form of Cas9 system utilizes two independent gRNAs to create proximal nicks in target DNA and greatly decreases off-target mutation events in the genome [30] .
We first confirmed CRISPR/Cas9n targeting of the ROSA26 locus. ROSA26-specific CRISPR/Cas9n components were transfected into CHME-5 cells followed by puromycin selection and regrowth (Fig. 1C) . A combination of Cas9n and ROSA26 gRNAs caused mutations and genetic diversity at the ROSA26 locus in CHME-5 cells as verified using the T7E1 assay [31] . Cas9n + gRNAs to ROSA26 showed evidence of nuclease activity at the ROSA26 locus but not at the control gRNA locus tyrosine hydroxylase (TH; Cas9n is used to create mutagenic events at ROSA26. The HIV-NanoLuc provirus is flanked by ROSA26 homologous arms to facilitate integration. (B) CHME5 cells were transfected with CRISPR/Cas9 components and gRNAs targeting the ROSA26 locus or TH as a control. Puromycin selection was performed to select cell populations that were successfully transfected. PCR was then performed on genomic DNA to amplify the ROSA26 or TH genomic sequences. T7 endonuclease 1 enzyme was added to identify mutagenic events and shows specific targeting of the ROSA26 locus in CHME-5 microglia by CRISPR/Cas9. Treatments are as follows: 1: PC12 cells + ROSA26 gRNA (positive control), 2: CHME-5 cells + no gRNA, 3: CHME-5 cells + ROSA26 gRNA, 4: CHME-5 cells + TH gRNA. (C) Photomicrographs of CHME-5 cells undergoing puromycin selection. (D) Transient transfection of the HIV-NanoLuc provirus in CHME-5 microglia results in luciferase activity. Mock transfection of pBSII or a CMV-driven NanoLuc was used as a negative and positive control, respectively. (E) CRISPR/ Cas9 at the ROSA26 locus was performed with the addition of the donor HIV-nanoLuc provirus. After puromycin selection, cells were clonally isolated in a 96-well plate and assayed for luciferase activity. Wells B1, B2: parental CHME-5, Red wells: low NanoLuc expression, Yellow wells: medium NanoLuc expression, Green wells: high NanoLuc expression.
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targeting TH did not show evidence of nuclease activity when ROSA26 was amplified (Fig. 1B) . These data suggest that the ROSA26 locus can be successfully targeted with CRISPR/Cas9n in CHME-5 microglia. Therefore, we proceeded with co-transfection of the CRISPR/Cas9n components and the HIV-NanoLuc targeting DNA. After transfection, puromycin selection, and regrowth, cells were plated at one cell per well in a 96-well plate and allowed to grow to confluency. We have previously observed detectable luciferase activity using transient transfections of our targeting construct (Fig. 1D) . Therefore, the luciferase assay was used to evaluate our stable clones. Following expansion, cells were replica-plated and assayed for luciferase which identified a wide range of NanoLuc values (Fig. 1E) . We chose four clones with relatively high levels of NanoLuc expression within the clonal populations to further characterize: E3, F3, D10 and E9. Two negative controls were included, parental CHME-5 cells and clone B2 that was subjected to transfection, puromycin selection and clonal expansion, but expressed background levels of NanoLuc (Fig 1D) . To confirm ROSA26-targeted integration of the HIV provirus, we PCR amplified the 5 0 junction, 3 0 junction, and the Env region of the HIV-NanoLuc provirus ( Fig. 2A) . The 5 0 junction primer pairs spanned from the 5 0 genomic region of ROSA26 through the NanoLuc gene within the provirus (purple arrows; expected size 2071 bp). The 3 0 junction primers spanned the Nef gene to the 3 0 end of the ROSA26 genomic region (green arrows; expected side 1786 bp). To determine if truncation of the provirus occurred, primer pairs spanning a 2285-bp region (orange arrows) of the Env gene were used. After PCR amplification, we verified that clones E3, D10 and E9 have integration of the provirus at the ROSA26 locus (Fig. 2B) . Furthermore, our negative controls showed no bands, suggesting PCR assays were performed on four clones with high NanoLuc expression; E3, F3, D10, E9 with parental CHME-5 and clone B2 serving as controls. Clones E3, D10 and E9 show expected bands for proper insertion. DDCPR was performed on the genomic DNA of HIV-NanoLuc clones E3, F3, D10, and E9 assaying for NanoLuc vs. autosomal gene GGT1. (C) Ratio of NanoLuc and GGT1 copy number. Table: Copy number of the provirus is ((copies/lL NanoLuc)/ (copies/lL GGT1)) 9 (2) = copy number per genome. (D) Stability of provirus integration was determined in clone E9. There is no change in copy number of the HIV provirus after multiple passages. specificity of our primer pairs. However, while clone F3 amplified the Env gene, improper products were observed for the 5 0 and 3 0 integration junctions. This may indicate off-target integration, or that recombination events occurred which altered the PCR primer sites.
We used Droplet-Digital PCR (ddPCR) to assay the number of HIV-NanoLuc provirus copies within the selected clones. We compared the number of copies of NanoLuc transgene and the autosomal reference gene Ggt1 (Fig. 2C) . Our results show multiple copies of the transgene sequence in clones E3, F3, D10 and E9. No amplification of NanoLuc was observed with parental CHME-5 or clone B2, our negative controls. To determine if provirus copy number is stable through multiple passages, we assayed the copy number of clone E9 at passage numbers 5, 10, 15, and 25. The copy number of the HIV provirus does not change (Fig. 2D) , indicating stable integration. We proceeded with the phenotypic characterization of clones E3, D10, and E9.
Phenotypic characterization of HIV-NanoLuc clones
For the following set of validation experiments, we evaluated clones with confirmed insertion of the provirus at the ROSA26 locus: E3, D10 and E9 (pictured in Fig. 3A ). We first examined each clonal line for response to a known activator of the HIV LTR promoter. We used lipopolysaccharide (LPS; 100 ngÁmL À1 ) as an inducer of the NF-jB transcription factor, which has been shown to bind to the HIV-LTR and enhance proviral activity [32] [33] [34] . Parental CHME-5 cells and clones D10, E3 and E9 were stimulated with LPS for 24 h and lysates were prepared. Clones E3 and E9 showed a significant increase in NanoLuc activity after LPS stimulation (Fig. 3B) . The lysates from these cells were also assayed for expression of the HIV protein, Nef. For clones E3 and E9, we observed a LPS induction of a 35-kDa Nef band (Fig. 3C ). Nef expression was further validated by immunohistochemistry using a Nef-specific antibody (Fig. 3D) . Clones E3 and E9 displayed Nef immunoreactivity. Further confirmation of antibody specificity was performed by mixing Parental CHME-5 cells with E9 cells, where Nef immunoreactivity was observed in only a portion of the population.
It is important to note that even though we confirmed stable provirus integration in clone D10, this clone failed to be responsive to LPS stimulation by both NanoLuc and Nef expression. To further understand the lack of proviral activation of clone D10, we analyzed the pro-inflammatory profile of our clones using a Luminex multiplex assay (Fig. 3E) . After LPS stimulation, parental CHME-5 cells and clone E3 and E9 display a significant induction of chemokines CXCL2 and CXCL3 while D10 does not show this effect. Furthermore, clone D10 constitutively expresses TIMP-1 several fold above the other cell lines. These data suggest that clone D10 may have a different cellular phenotype, thus altering its ability to activate the provirus. Overall, these data demonstrate the methodology and experimental caveats in using the CRISPR/ Cas9 system to facilitate the integration of a modified HIV provirus to the genome of CHME-5 cells. Clone E9 was chosen for further characterization due to its robust NanoLuc expression, inducible Nef production, and pro-inflammatory phenotype. Now referred to as HIV-NanoLuc E9, we performed a series of experiments to determine the potential of this cell line for evaluating therapeutic strategies to modulate proviral activity in microglia.
Enhancing proviral activity in the HIV-NanoLuc E9 cell line
The presence of a LTR-driven NanoLuc reporter enables us to easily monitor proviral activity. Therefore, we ran a battery of different experiments in a 96- ) stimulation. We observe time increases in CXCL-2 and CXCL-3 by parental CHME-3, E3 and E9 cells (Green cells, P < 0.01). D10 cells failed to produce these effects. Additionally, D10 cells constitutively express TIMP-1 at a concentration much higher than other cell lines (orange cells). Data are expressed as the mean AE SEM for (B) . N = 3 independent cell passages. Data are expressed at the mean AE SD for (E). N = 2 independent cell passages. well plate format to either enhance or inhibit proviral activity in HIV-NanoLuc E9 cells. We first compared our previously shown LPS response ( Fig. 3B ) to proinflammatory mediator TNF-a, a pro-inflammatory cytokine that promotes NF-jB signaling and activates latent HIV provirus [15] . Cells were treated with LPS (100 ngÁmL
À1
) or TNF-a (50 ngÁmL
) by media exchange in a reverse time course for 72, 48, or 24 h (Fig. 4A1 ). The cells were lysed and luciferase activity was measured for each timepoint. LPS enhanced NanoLuc activity at 24 h of stimulation, which decreased with longer treatment times of 48 and 72 h (Fig. 4A2 ). At the concentrations tested, TNF-a showed a stronger stimulatory effect in enhancing NanoLuc activity compared with LPS ( Fig. 4A2,A3 ). We next wanted to establish if multiple treatments with pro-inflammatory factors would further drive proviral activity. HIV-NanoLuc clone E9 cells were stimulated 19, 29, or 39 times with LPS or TNF-a by full media exchange and NanoLuc levels were assayed (Fig. 4B1) . A single (19) treatment of LPS increased luminescence over untreated control. A 39 treatment of LPS showed a significant enhancement of proviral activity over 19 treatment (Fig. 4B2 ). TNF-a also increased NanoLuc activity after single (19) treatment, and further increased activity at 29 and 39 treatments (Fig. 4B3) . Therefore, multiple pro-inflammatory stimulations can promote proviral activity.
Because the previous experiments examined proinflammatory factors that work on a cell surface receptor [e.g. toll-like receptor (TLR-4) and TNF-a receptor (TNFR)], we wanted to determine if intracellular components directly involved with viral replication would also drive proviral activity. Tat is a regulatory protein that enhances HIV proviral transcription, and Rev facilitates transport of full-length provirus from the nucleus [35] . We developed two plasmids that express myc-tagged viral proteins Tat-myc and Rev-myc that are under control of the CMV promoter (Fig. 4C ).
These two plasmids were transfected into HIV-NanoLuc clone E9 cells for 48 h, and proviral activity was determined by luciferase. LPS was used as a positive control and pBluescript II SK (+), or pBSII, plasmid was used as a transfection control (Fig. 4D) . We observed that transfection with pBSII increased NanoLuc activity which may be due to contamination of the plasmid with bacterial endotoxin or the process of transfection activating cellular processes that have downstream effects on the provirus. Transfection of pRev-myc had similar effect as pBSII. However, transfection with pTat-myc significantly enhanced proviral activity to levels similar to LPS. These data suggest that overexpression of the HIV viral protein Tat can drive expression of the proviral construct.
Inhibiting proviral activity in the HIV-NanoLuc (E9) cell line Our next set of experiments aimed to inhibit proviral activity by genetic and pharmacological means. We tested the ability of CRISPR/Cas9 to alter the LPS response observed in HIV-NanoLuc E9. Specifically, we utilized gRNAs in combination with wild-type Cas9 to mutate the TLR-4 receptor, a primary receptor for LPS, in order to decrease LPS-mediated proviral activation. We performed TLR-4 targeted CRISPR/Cas9 mutagenesis and puromycin selection (as previously performed in Fig. 1 ) on cell populations of HIV-NanoLuc E9 cells. Confirmation of mutagenesis in the TLR-4 gene was achieved by using the T7E1 assay (Fig. 5A) . After stimulating mixed populations of TLR-4 mutant cells and non-TLR-4 mutant cells with LPS for 24 h, we observed that TLR-4 mutants showed less induction by LPS (CRISPR@TLR4; 1.17-fold) compared with the control cells (HIV-NanoLuc E9 or CRISPR@TH; 1.43-fold and 1.52-fold, respectively; Fig. 5B ). To further confirm the observed effects were due to TLR4 mutagenesis and not an . We observed significant increases in luciferase activity after simulation with both LPS (A.2) and TNF-a (A.3). Significant induction persists up to the 72-h time point. LPS: **P < 0.0001, *P < 0.0002; TNF-a: ****P < 0.0001. (B) Cells were treated 19, 29, or 39 with LPS or TNF-a to determine if proviral activity could be increased by multiple treatments (timeline in B.1). There is a significant effect of proviral induction with multiple treatments of pro-inflammatory factors; LPS (B.2), TNF-a (B.3). LPS: *P < 0.0001 vs. Untreated, # P < 0.001 vs. 19 treatment; TNF-a: *P < 0.0001 vs. Untreated, # P < 0.0001 vs. 19 treatment,^P < 0.0004 vs. 29 treatment. (C) Myc-tagged HIV protein expression plasmids were developed from their corresponding coding sequence in the provirus. Plasmids were transfected into HEK293 cells for expression testing and Wes analysis was performed to confirm protein expression. (D) E9 cells were transfected with pTat-myc and pRev-myc to determine the effect of HIV regulator proteins on proviral activity. LPS was used as a positive control for induction, and pBSII plasmid was used as a transfection control. pRev-myc transfection produced the same relative NanoLuc levels as pBSII transfection. pTat-myc significantly increased NanoLuc activity similar to the levels of LPS. *P < 0.05 vs. untreated, **P < 0.0001 vs. untreated. Data are expressed as the mean AE SEM. N = 3 independent cell passages. overall decrease in inflammatory response, the same cell types were stimulated with TNF-a which does not signal via TLR-4. Each cell type exhibited similar changes in response to TNF-a stimulation (HIV-NanoLuc E9, 3.9-fold; CRISPR@TH, 4.1-fold; and CRISPR@TLR4, 4.2-fold; Fig. 5C ). NF-jB is an established transcription factor that regulates HIV proviral activity. We tested whether the NF-kB inhibitor sulfasalazine could block LPSmediated proviral activation. Sulfasalazine (0.1, 0.5, or 1 mM) was prepared in serum-free media and added to HIV-NanoLuc E9 cells 1 h before LPS (100 ngÁmL À1 ) stimulation. We observed that 1 mM sulfasalazine inhibited LPS-mediated proviral activity (Fig. 5D) . We observed no difference in ATP activity among sulfasalazine concentrations or LPS stimulation indicating the loss of NanoLuc activity is not due to decreased cell viability (Fig. 5E) . Photomicrographs of the wells also indicated that no cell loss occurred as a result of the treatments (Fig. 5F ). Overall, the data from characterization of HIV-NanoLuc E9 cells show that the modified HIV provirus can be manipulated in pharmacological, viral, and molecular means consistent with the known biology of the HIV provirus.
Targeting the HIV-NanoLuc provirus with CRISPR/Cas9
The CRISPR/Cas9 gene editing system has also been utilized to mutate and excise a provirus which leads to decreased proviral activity, replication, and subsequent re-infectivity [28] . In addition, other investigators have observed proviral escape and establishment of 'CRISPR/Cas9' resistant strains of HIV [36, 37] . Our next aim was to determine if CRISPR/Cas9 could be directly used on the provirus within the HIV-NanoLuc CHME-5 E9 line and determine if proviral activity can be altered. We developed two gRNA sequences (LTR gRNA A and LTR gRNA B) to target the LTR of our provirus (Fig. 6A) . LTR gRNA A targets a region similar to previously published studies, while LTR gRNA B targets within an untested region of a NFjB-binding site. We tested these gRNAs on the HIVNanoLuc CHME-5 E9 cell line in combination with Cas9. Transfection with Cas9 alone was used as a control. These treated cells were then plated onto a 96-well plate at equal cell density, stimulated with LPS (100 ngÁmL
À1
) or TNF-a (50 ngÁmL À1 ), and luciferase was assayed 24 h post stimulation. We observe that LTR gRNA 2 resulted in a significantly decreased luciferase value under basal conditions, and after stimulation with pro-inflammatory factors (Fig. 6B) . Furthermore, we determined the mutagenic effects of the gRNAs on the HIV LTR and assessed proviral excision/mutation. We developed primers within the HIV LTR region (Table 1 ) and amplified a 620-bp product from the genomic DNA of mutated cell lines. The T7E1 assay was the performed and produced the expected splice products for LTR gRNA 2 (358 bp and 262 bp), suggesting CRISPR/Cas9 mutated the target site (Fig. 6C) . Finally, DDPCR was performed using NanoLuc primer and probe sets as previously described in Fig 2C,D . LTR gRNA 2 treatment decreased ratio of the NanoLuc to GGT1, indicating a significant reduction of proviral genome copies per cellular genome (Fig. 6D) . Overall, these experiments demonstrate that the HIV-NanoLuc CHME-5 E9 cell line can also be a useful model to test gRNAs targeting the HIV provirus. Furthermore, the presence of NanoLuc allows for a rapid assay of proviral activity after gRNA targeting in a 96-well plate format, allowing you to combine gRNA treatment pharmacological stimulation in one plate. Finally, the stability of the provirus allows for the assay of proviral excision efficiency, a factor that is not easily achieved in productive viral infection.
Discussion
This study describes the development and characterization of a reusable microglia cell line for the study of HIV pathobiology in microglia. We use CRISPR/Cas9 technology to facilitate targeted integration of a modified HIV provirus to the safe harbor locus ROSA26. ) with untreated E9 cells, and E9 cells receiving TH gRNAs were used as a comparison. ***P < 0.0001 vs. untreated, *P < 0.05 vs. untreated. Average fold changed listed above graph. #P < 0.05 vs. fold change of HIV-NanoLuc CHME-5 E9. (C) Cells were treated with TNF-a (50 ngÁmL À1 ) to show that the LPS effect is specific to TLR-4 mutation. ***P < 0.0001 vs. untreated. Average fold changes listed above graphs. No significant difference vs. fold change of HIV-NanoLuc CHME-5. (D) Inhibition of proviral activity using NF-jB inhibitor sulfasalazine. Sulfasalazine (0.1, 0.5, or 1 mM) was added to cells 1 h before LPS (100 ngÁmL We show that the HIV provirus was successfully integrated at the targeted locus in three of our chosen clonal lines. The provirus is also active in clones E3 and E9, producing the NanoLuc reporter and the HIV viral protein Nef after activation by LPS, while still maintaining the same inflammatory profile as parental CHME-5 cells. Furthermore, a battery of experiments using HIV-NanoLuc E9 reveals that this cell line is a useful model for identifying changes in proviral activity after pharmacological, viral, and molecular manipulations. Overall, HIV-NanoLuc E9 may be used as a first step in proviral experimentation to determine optimal conditions before transitioning to primary cells, live virus, and in vivo models. However, throughout the experimental procedures of this manuscript, there are several important aspects to review. CRISPR/Cas9 technology has been widely regarded for its efficient and targeted genome modification. In this study, we used this technique to facilitate homologous recombination and insertion of our modified provirus. Interestingly, while we do observe proper insertion of the provirus at ROSA26 (validated by cross junction PCR, Fig. 1F ), there is evidence of off-target insertion. Clone F3 failed to show junction PCR products, despite confirming genomic presence of the provirus by successfully amplifying the Env gene. Using droplet digital PCR, we identified multiple copies of NanoLuc in all the clones that were picked by screening for > 10 000 luciferase activity, possibly indicating additional proviral insertions. Although we used Cas9n to minimize off-target effects [38] , we do not know whether the additional integrations are due to off-target effects of CRISPR or the random insertion of donor DNA into the genome. Despite this caveat, we were able to obtain stable microglial cell lines with a modified HIV provirus targeted to the ROSA26 locus.
The effect that HIV infection and integration has on the inflammatory profile in microglia is varied. Typically infection enhances secretion of pro-inflammatory factors such as IL-1b and TNF-a [39] and results in a dysregulation of glutamate homeostasis and release of detrimental metabolites [40] with alterations in metabolic processes and caspase activation [5, 41] . However, our Magpix analysis reveals that clones E3 and E9 continue to produce inflammatory factors that are comparable to the profile of parental CHME-5 microglia (Fig. 2E) . The largest difference observed was with clone D10, which not only appears to be unable to respond to LPS stimulation but displays a different inflammatory profile (e.g. no/low induction of CXCL-2/3, constitutive expression of TIMP-1). This may be due to random integration events or Cas9n events that change the overall phenotype away from a M1-like microglia (pro-inflammatory) to one that resembles M2 (anti-inflammatory). There is evidence of HIV-infected microglia from human subjects that have a decreased expression of pro-inflammatory factors after LPS stimulation [42] . Furthermore, newer evidence supports the role of TIMP-1 expression as a neuroprotective factor against HIV-mediated neurotoxicity [43] . Therefore, a subset of infected microglia may change to this anti-inflammatory phenotype which can contribute to evasion and identification by host immune responses, leading to establishment of viral reservoirs within the CNS. Further study is needed to explore this hypothesis.
Using clone HIV-NanoLuc E9, we demonstrate its potential as a model to rapidly assess proviral activity by a variety of methods. Previous HIV proviral reporter cell lines and constructs have utilized GFP, and subsequently flow cytometry, as a readout of activity [28, 44] . Because our proviral construct contains the luciferase NanoLuc, we can easily assess proviral activity using a luminescence assay in high throughput formats (i.e. 96-well plates), bypassing the need for time-consuming flow cytometry measures. However, if population studies are still desired by FACS sorting or flow cytometry, the Nef protein is highly expressed in this cell line (Fig. 2D ) and could be used as a target protein for immunolabeling with a fluorophore.
In our studies enhancing the proviral activity in HIV-NanoLuc E9 cells, we show longitudinal activation, repeated activation, and comparative activation between two pro-inflammatory factors, LPS and TNF- Fig. 6 . CRISPR/Cas9 Targeting of HIV-NanoLuc Provirus. Two gRNAs (LTR gRNA A and LTR gRNA B) were developed to perform CRISPR/ Cas9 directed mutagenesis on the HIV-NanoLuc provirus in HIV-NanoLuc CHME-5 E9 cell line. (A) Schematic of the HIV-NanoLuc LTR region denoting transcription sites and gRNA targeted regions. Yellow arrows denote gRNAs used for the subsequent experiments. Table: Overview of gRNA binding sites, target region, cut site, and sequence comparison with published studies. (B) HIV-NanoLuc CHME-5 E9 cells were transfected with Cas9 AE LTR gRNA A or LTR gRNA B. After passaging, cells were plated on at 96-well plate and stimulated with LPS (100 ngÁmL À1 ) or TNF-a (50 ngÁmL
À1
) for 24 h. Luciferase assay shows a significant reduction of proviral activity using gRNA B *P < 0.05 vs. HIV-NanoLuc CHME-5 E9. (C) T7E1 mutagenesis assay was performed using LTR-specific primers and confirms mutagenesis by Cas9 + LTR gRNA B. (D) DDPCR was performed to determine changed in copy number of integrated HIV-NanoLuc provirus. Cas9 + LTR gRNA B significantly lowered the copy number of integrated provirus P < 0.05 vs. HIV-NanoLuc CHME-5 E9. Data are expressed as the mean AE SEM. N = 3 independent cell passages.
a (Fig. 3) . We observed that proviral activity decreased over time after a single treatment with LPS but not with TNF-a treatment, suggesting a prolonged state of proviral activity. Additional studies, such as dose-response curves, may be performed to elucidate the difference in magnitude in luminescence observed after stimulation between LPS and TNF-a. Indeed, proviral 'activators' may not be equal in their potency. Some factors that may play a role in this effect may be the difference in expression between the TLR4 and TNFR, respectively. One study has shown that reactivation of latent HIV provirus by TNF-a differs by cell types (both primary and immortalized) and this was contingent on TNFR expression [45] . With this in mind, HIV-NanoLuc E9 cells may be utilized to quantitatively measure and compare compounds (e.g. other cytokines/chemokines, drugs of abuse, and co-infection with other viruses) with their ability to activate proviral activity.
The use of CRISPR/Cas9 has been applied to the study of HIV. For example, recreation of the CCR5D32 mutation that renders cells immune to HIV infection has been applied in human cell studies [46] , and Cas9 + gRNAs targeted to regions of the provirus (e.g. LTR, Gag-Pol, Env) can excise the provirus and knock down viral activity [28, 44] . In this study, we target the cellular receptor TLR4 by CRISPR/Cas9 and show a reduction in LPS-stimulated proviral gene expression. Bacterial infection and subsequent LPS circulation during HIV infection continues to be a comorbidity concern due to constitutive activation of the provirus by LPS [47] . Our TLR4 mutation supports the use of therapies that target toll-like receptors to modify proviral activity. As a model, the HIVNanoLuc E9 cells can be used for further studies involving pharmacological and CRISPR-mediated manipulations of proviral activity. Using this cell line, we were able to perform CRISPR/Cas9 targeting of the HIV LTR region. We show not only proviral mutation and excision, but also decreased proviral activity after stimulation with pro-inflammatory factors, further supporting the use of this cell line for CRISPR-mediated experimentation. Future studies may include a compatible CRISPR library screen [48] which could be used to identify genes that alter HIV proviral activation/reactivation in microglial cells.
We have previously used the CHME-5 microglial cell line for HIV LTR expression studies [32] and chose it as our surrogate microglia for integrating a modified HIV provirus. However, proviral activity is subject to the phenotype of host cells. For CHME-5 cells, we did not observe increased secretion of proinflammatory cytokines after LPS stimulation (Fig. 2E) . This is not surprising as it has been characterized that CHME-5 cells require a cytomix formula (e.g. interferon-c, TNF-a, IL1-b) to produce proinflammatory substances such as nitric oxide [25] . Furthermore, by using rat-specific gRNAs and PCR assays in our experiments, we confirmed that CHME-5 cells are derived from rat. Overall, new microglia models would be beneficial in conjunction with the CRISPRmediated integration technique. At least two investigators have developed techniques to produce reusable human microglia either through immortalization [27] or cell preparation [49] , and as these cell lines become more readily available, integrating our HIV-NanoLuc provirus would be of value to compare the inflammatory profile and proviral effects between the cell lines. Collectively, we describe the creation of an in vitro model for studying the pathobiology of HIV in microglia. Having a renewable microglia cell line with a stably integrated HIV provirus may provide a foundational starting point for many NIH-AIDS priority investigations. For example, this model is amenable to pharmacological manipulation to alter HIV proviral gene expression, which may facilitate experimentation into next-generation compounds that either suppress or activate latent HIV proviral activity (i.e. the 'kick and kill' hypothesis). As precedence, the CHME-5 cell line has previously been used to test antiretroviral compounds [25] . The addition of the HIV-NanoLuc provirus into CHME-5 cells will allow for rapid assay of proviral activity by luciferase, in addition to a pro-inflammatory screen (Fig. 3E ) and viability assay (Fig. 5E ) all in one cell line. This will allow for identification of compounds that have a combination of high therapeutic effects, but with minimal inflammatory and toxicity profiles. Furthermore, because the original cell line is microglia derived, experiments can be performed to understand provirus regulation in a cell type that is part of the HIV 'viral reservoir'. Microglia are dynamic cells, and it would be of interest to uncover how proviral activity is regulated under classical microglia functions including phagocytosis, migration, and scavenging. Comorbidity studies, such as HIV and drug abuse, are also of high priority in AIDS-related research. Our laboratory has previously shown that methamphetamine enhances LTR activity in CHME-5 cells [32] . Future experiments could include treatments of methamphetamine and other drugs of abuse (e.g. morphine, heroin, and cocaine) on the HIV-NanoLuc CHME-5 E9 cell line to assay effects of proviral activation/deactivation by these compounds. Overall, this cell line provides an additional model for the study of HIV proviral activity and regulation in microglia.
Materials and methods
Cell culture and transfections CHME-5 microglia were grown in microglia growth media: High glucose Dulbecco's modified Eagle's medium (DMEM; Gibco/Thermo-Fisher, Waltham, MA, USA) supplemented with 5% FBS (Hyclone/GE, Logan, UT) and 1% penicillin/streptomycin (Gibco). Cells were passaged every 4 days using 0.01% trypsin (Gibco). Transfections of CHME-5 cells were carried out using LipofectamineÒ 2000 (Thermo-Fisher) according to the manufacturer's instructions.
CRISPR/Cas9

ROSA26 targeting by Cas9 nickase system
A Cas9-nickase-based system was used for targeted integration of the modified HIV provirus into the ROSA26 locus. A Cas9n [30] -compatible pair of gRNAs was designed using the crispr.mit.edu website and cloned into the BbsI restriction sites of the pX462-pSpCas9n(BB)-2A-Puro construct [50] (Addgene #48141; Table 1 ). pspCas9n(BB)-2A-Puro [PX462] was a gift from Feng Zhang (Addgene plasmid #48141). A similar workflow was used to create a pair of gRNAs for TH as a control. The gRNA/Cas9n constructs were tested by co-transfection into CHME-5 microglia cells and assaying for heterogeneity at the ROSA26 locus by the T7E1 assay.
DNA constructs
A replication-defective HIV provirus was constructed by replacing the final 1500 nucleotides of gag region and the leading 2306 nucleotides of the pol region of pYU2 [51, 52] (GenBank #M93258) with a loxP site and the coding region for NanoLuciferase (NanoLuc). The pYU2 plasmid was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH and donated thereby B. Hahn and G. Shaw. The entire proviral sequence (bounded by and including the flanking LTRs) was transferred into a backbone containing sequences homologous to 1021 nucleotides upstream and 998 nucleotides downstream of the Rosa26-targeted CRISPR-induced breakpoint (pOTTC1085, Addgene 89306). The homology-flanked modified provirus was then modified further by replacement of the LTR with the intermediate-early promoter from human cytomegalovirus (CMV-IE) using ligation-independent cloning (pOTTC1166, Addgene 89307). The epitope-tagged HIV protein expression constructs were created by amplifying the appropriate ORF using pYU2 as a template, or by synthesizing a 'spliced' form of a discontiguous ORF using the sequence of pYU2 as a guide, and recombining these inserts with pCMV6-Entry vector (Origene, Rockville, MD, USA). See Table 2 for Addgene #s.
Provirus integration by CRISPR/Cas9
Provirus integration through homologous recombination was performed on CHME-5 microglia in a 6-well plate by lipofectamine transfection of Cas9-nickase + gRNA constructs (1 lg of each gRNA per well) plus the HIV provirus (2 lg per well). Forty-eight-hour post-transfection, cells were split into a new dish, and puromycin (Thermo/Fisher) selection (2 lgÁmL À1 ) was performed for another 48 h.
Dead cells were washed off with 19 PBS and microglia growth media was added. Surviving cells were allowed to recover for 4 days, after which they were split and plated at one cell per well in a 96-well dish. Cells were incubated and single-cell clonal populations were confirmed by visualization under a microscope. Nonsingle-cell clonal populations were excluded when passaging the plate. After cells were grown to confluence replica, plating was performed to assay for proviral integration by the luciferase assay.
TLR-4 knock out by CRISPR/Cas9
A guide-RNA sequence ( 
HIV NanoLuc LTR Targeting by CRISPR/Cas9
Two guide-RNA sequences (LTR gRNA A and LTR gRNA B; see Fig. 6A ) were developed to target the HIVNanoLuc LTR region. The gDNA was cloned into the pGuide-it backbone (Takara, Mountain View, CA, USA). HIV-NanoLuc CHME-5 E9 cells were transfected twice with Cas9 + LTR gRNA A/B and a stable population of cells was established for experimentation. HIV-NanoLuc LTR-specific primer sets (Table 1) were utilized to determine mutagenesis by the T7E1 assay.
Genomic DNA preparation and PCR analysis
The genomic DNA was isolated using the NucleoSpinÒ Tissue Column (Macherey-Nagel Bethlehem, PA, USA) according to the manufacturer's instructions. DNA concentrations were measured using a Nanodrop 2000 (Thermo-Fisher). PCR reactions were prepared using Phusion High Fidelity GC Buffer (New England Biolabs, Ipswich, MA, USA) with 5 lM forward and reverse primers. Primers are listed in Table 1 
Droplet digital PCR
The relative copy number per genome of the modified HIV provirus was determined using Droplet Digital PCR (BioRad-QX200) to quantify the number of provirus templates per microliter for the NanoLuc transgene relative to the autosomal reference gene GGT1. Primers and probes used are listed in Table 1 . Reaction conditions consisted of a master mix containing: 19 ddPCR TM Supermix for Probes no dUTP (Bio-Rad), 450 nM forward and reverse primers, 50 nM probe, 0.1 U MseI restriction enzyme with 50-ng genomic DNA. Reactions were run analyzing NanoLuc and GGT1 simultaneously as a duplex reaction. Equation for calculating copy number is ((copies/lL NanoLuc)/ (copies/lL GGT1)) 9 (2) = copy number per genome.
T7E1 assay for CRISPR-mediated mutagenesis
The T7 Endonuclease 1 enzyme-'T7E1' (New England Biolabs) was used to detect mutations in the ROSA26 and TLR4 PCR amplified region. Amplified products were denatured and slowly annealed in NEBuffer 2 (New England Biolabs) using the following cycle: 95°C 5 min, 85°C 30 s ? ramp 2°C 5 s À1 , 25°C 30 s ? ramp 0.1°CÁs À1 , 25°C hold. T7E1 was then added to the reannealed products and incubated at 37°C for 1 h. DNA was run on a 1% agarose gel and presence of T7E1 digestion was used to verify CRISPR/Cas9-mediated mutation.
Cell culture treatments CHME-5 or HIV-NanoLuc CHME-5 was stimulated with LPS or TNF-a. Lipopolysaccharide (LPS) (Cat#L3012;
Sigma-Aldrich, Allentown, PA, USA) was used at a 100 ngÁmL À1 concentration in microglia growth media [54] .
Tumor necrosis factor-a (TNF-a) (Cat#T5944; SigmaAldrich) was used at a 50 ngÁmL À1 concentration in microglia growth media [55] . For repeated treatments of LPS and TNF-a, full media exchange with diluted compounds were performed. Sulfasalazine experiments were carried out in serum-free media with full media exchange. Sulfasalazine (Cat# 4935; Tocris Biosciences, Bristol, UK) was pre-incubated at a 0.1, 0.5, and 1 mM on cells for 1 h. After the incubation time, LPS was added by spiking the media to a 100 ngÁmL À1 final concentration.
Western blot analysis (Wes)
Cell lysates for Wes (ProteinSimple, San Jose, CA, USA) analysis were produced using RIPA buffer (50 mM Tris HCl pH 7.5, 0.25% sodium deoxycholate, 150 mM NaCl, and 1 mM EDTA) with 1% NP40 detergent (ThermoFisher) and protease inhibitor (Sigma-Aldrich). Cells were lysed for 20 min on a rotating plate at 4°C, after which lysates were collected, and spun down for 10 min at 9400 g in a microcentrifuge. The supernatant was extracted and protein levels were read using the BCA assay (ThermoFisher). The Wes was run using 400 lgÁmL 
Luciferase assay
Cells that were prepared for luciferase assay were lysed directly in an opaque 96 well using RIPA lysis buffer/1% NP 40 with protease inhibitor as previously described [56] . Luminescence was measured in the opaque plate using the substrate coelenterazine (Regis Technologies, Morton Grove, IL, USA) in a Bio-Tek Synergy 2 plate reader (Winooski, VT, USA).
Cell viability
Cell viability was assessed using CellTiter-Glo ATP assay (Promega, Fitchburg, WI, USA) according to the manufacturer's instructions.
Immunohistochemistry CHME-5 microglia and clones were washed with 19 PBS and fixed with 4% paraformaldehyde solution for 30 min.
Cells were then permeabilized using blocking buffer with triton x-100 for 30 min, after which the primary antibody (Nef, 1 : 500 dilution) was added. The following reagent was obtained through the AIDS Reagent Program, Division of AIDS, NIAID, NIH: Nef Antibody Cat# 3689 from J. Hoxie. Secondary antibody Alexa FluorÒ 488 (Cat# Z25002; Thermo-Fisher and 1 : 1000) was added for 1 h to determine fluorescence.
Magpix multiplex analysis
Media taken from cell lines AE LPS stimulation (100 ngÁ3mL À1 for 24 h) were run on a Luminex Multiplex Cytokine Array (Cat#LXSAR-M, R&D, Minneapolis, MN, USA) and analyzed on a MagpixÒ System (Millipore) according to the manufacturer's instructions.
Statistical analysis
All analyses were evaluated by GRAPHPAD Prism, GRAPHPAD Software (La Jolla, CA, USA). Data were analyzed with oneway ANOVA with Tukey's multiple comparisons test. Data that compared two factors (e.g. sulfasalazine experiments) utilized two-way ANOVA with Tukey's multiple comparisons test. Data are expressed as the mean AE SEM. Data from Magpix analysis expressed as mean AE SD. Statistically significant differences were considered as P < 0.05.
